266 results on '"Meroni, Marica"'
Search Results
2. The Alpha-Lipoic Acid Improves Glucose Metabolism and Hyperinsulinemia in Acute Intermittent Porphyria: A Nutritional Concept for the Management of Rare Disorders
3. Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades
4. A novel gene signature to diagnose MASLD in metabolically unhealthy obese individuals
5. Artificial intelligence as a ploy to delve into the intricate relationship between genetics and mitochondria in MASLD patients
6. WED-218 Circulating mitochondrial bioenergetic profile reflects the hepatic one and represents a non-invasive biomarker of disease severity in MASLD genetically predisposed individuals
7. FRI-544 KLB depletion fosters stem-like properties and epithelialmesenchymal transition plasticity in HepG2 cells
8. A narrative review about cognitive impairment in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Another matter to face through a holistic approach
9. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin
10. Serum mitochondrial bioenergetics as fingerprint of the hepatic one: how to monitor genetic MASLD
11. Hepatic and adipose tissue transcriptome analysis highlights a commonly deregulated autophagic pathway in severe MASLD
12. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
13. Cholesterol-Associated Locus EHBP1 Protects Against MASH Fibrosis
14. Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?
15. Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis
16. PNPLA3 rs738409 Genetic Variant Inversely Correlates with Platelet Count, Thereby Affecting the Performance of Noninvasive Scores of Hepatic Fibrosis
17. Recent advances of drugs monitoring in oral fluid and comparison with blood
18. Programmed cell death 1 genetic variant and liver damage in non-alcoholic fatty liver disease
19. Combined hepatic and adipose tissue transcriptomics highlights circulating NASH biomarkers
20. The overexpression of TM6SF2 and/or MBOAT7 wild-type genes restores the mitochondrial lifecycle and activity in an in vitro NAFLD model
21. b-Klotho deficiency in hepatic stellate cells (HSCs) prompts inflammation, oxidative stress and a pro-fibrotic phenotype
22. PNPLA3, MBOAT7 and TM6SF2 modify mitochondrial dynamics in NAFLD patients: dissecting the role of cell-free circulating mtDNA and copy number
23. Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆” [J Hepatol (2020) 505–515]
24. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease
25. The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
26. An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians
27. Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis
28. Circulating Indian Hedgehog is a Marker of the Hepatocyte-TAZ Pathway in Experimental NASH and is Elevated in Humans with NASH
29. Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
30. Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
31. Comparison of hepatic and cardiovascular damage between HIV patients with steatosis and NAFLD: role of metabolic alterations and low visceral adiposity
32. The co-presence of PNPLA3, MBOAT7 and TM6SF2 loss-of-functions impairs mitochondrial morphology and number in severe NAFLD patients
33. Increased burden of inherited IRF3 rare genetic variants in Europeans with severe Non-alcoholic fatty liver diease
34. The I48M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in non-alcoholic fatty liver disease (NAFLD) patients gains value
35. The overexpression of TM6SF2 and/or MBOAT7 wild-type genes re-establishes the mitochondrial dynamics in an in vitro NAFLD model.
36. The different modulation of KLB expression impacts on liver damage in NAFLD patients and in an in vitro model: a novel druggable target?
37. Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b
38. Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution
39. PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease
40. Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
41. Old-fashioned and newly discovered biomarkers: the future of NAFLD-related HCC screening and monitoring
42. Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system
43. Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
44. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
45. MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients
46. Genetics Is of the Essence to Face NAFLD
47. α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study
48. The rs2294918 E434K Variant Modulates Patatin-Like Phospholipase Domain-Containing 3 Expression and Liver Damage
49. The rs599839 A>
50. The α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.